⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for recurrent plasma cell myeloma

Every month we try and update this database with for recurrent plasma cell myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT01946152
Multiple Myelom...
Recurrent Plasm...
Refractory Plas...
Dexamethasone
Filgrastim-sndz
Laboratory Biom...
Pomalidomide
18 Years - M.D. Anderson Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerNCT00723099
Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Myeloge...
Chronic Phase C...
Indolent Non-Ho...
Lymphoma
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Plasm...
Recurrent Small...
Recurrent T-Cel...
Refractory Chro...
Refractory Chro...
Refractory Foll...
Refractory Hodg...
Refractory Lymp...
Refractory Mant...
Refractory Smal...
T-Cell Non-Hodg...
Allogeneic Hema...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Total-Body Irra...
Umbilical Cord ...
- 69 YearsFred Hutchinson Cancer Center
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT03333746
Recurrent Plasm...
Refractory Plas...
Laboratory Biom...
Lenalidomide
Nivolumab
Pharmacological...
18 Years - Ohio State University Comprehensive Cancer Center
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With LenalidomideNCT01794039
Recurrent Plasm...
Refractory Plas...
Dexamethasone
Lenalidomide
Pomalidomide
18 Years - Mayo Clinic
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple MyelomaNCT05288062
Plasma Cell Mye...
Recurrent Plasm...
Refractory Plas...
Smoldering Plas...
Bone Marrow Bio...
Dexamethasone
Lenalidomide
Pomalidomide
18 Years - Mayo Clinic
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple MyelomaNCT02504359
Plasma Cell Leu...
Recurrent Plasm...
Allogeneic Hema...
Carmustine
Cytarabine
Etoposide
Ixazomib Citrat...
Melphalan
Methotrexate
Peripheral Bloo...
Quality-of-Life...
Tacrolimus
18 Years - 65 YearsOHSU Knight Cancer Institute
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT01989598
Recurrent Plasm...
Refractory Plas...
Laboratory Biom...
Pharmacological...
Trametinib
Uprosertib
18 Years - National Cancer Institute (NCI)
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantNCT03015792
Recurrent Plasm...
Refractory Plas...
Dexamethasone
Ibrutinib
Laboratory Biom...
Lenalidomide
Pharmacological...
Quality-of-Life...
18 Years - Mayo Clinic
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple MyelomaNCT03710421
Recurrent Plasm...
Refractory Plas...
CS1-CAR T Thera...
Cyclophosphamid...
Fludarabine
Leukapheresis
18 Years - City of Hope Medical Center
Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaNCT02697344
Recurrent Plasm...
Dexamethasone
Laboratory Biom...
Lenalidomide
Pharmacological...
R-(-)-Gossypol ...
18 Years - Mayo Clinic
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple MyelomaNCT00966693
Recurrent Plasm...
Refractory Plas...
Dexamethasone
Lenalidomide
Thalidomide
18 Years - M.D. Anderson Cancer Center
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH TrialNCT05514990
Recurrent Plasm...
Refractory Plas...
Bortezomib
Dexamethasone
Pelareorep
Pembrolizumab
18 Years - University of Southern California
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 RearrangementNCT02765854
Recurrent Plasm...
Refractory Plas...
Dexamethasone
Ixazomib
Lenalidomide
18 Years - Emory University
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantNCT01822509
Allogeneic Hema...
Myeloproliferat...
Recurrent Acute...
Recurrent Acute...
Recurrent Chron...
Recurrent Chron...
Recurrent Hemat...
Recurrent Hodgk...
Recurrent Myelo...
Recurrent Non-H...
Recurrent Plasm...
Ipilimumab
Laboratory Biom...
Nivolumab
18 Years - National Cancer Institute (NCI)
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesNCT04205409
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Non-H...
Recurrent Plasm...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Marg...
Refractory Non-...
Refractory Plas...
Recurrent Mantl...
Refractory Mant...
Nivolumab
18 Years - University of Washington
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaNCT04508790
Recurrent Plasm...
Refractory Plas...
Dexamethasone
Leflunomide
Pomalidomide
18 Years - City of Hope Medical Center
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT03399539
Recurrent Plasm...
t(11;14)
Dexamethasone
Ixazomib Citrat...
Laboratory Biom...
Venetoclax
18 Years - Mayo Clinic
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple MyelomaNCT04579523
Plasma Cell Mye...
Recurrent Plasm...
Refractory Plas...
Allogeneic Hema...
Astatine At 211...
Cyclophosphamid...
Fludarabine Pho...
Total-Body Irra...
18 Years - 70 YearsFred Hutchinson Cancer Center
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT03763162
Recurrent Plasm...
Refractory Plas...
Bortezomib
Daratumumab
Dexamethasone
Ixazomib
Quality-of-Life...
18 Years - M.D. Anderson Cancer Center
Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple MyelomaNCT05411497
Recurrent Plasm...
Refractory Plas...
Autologous MUC1...
Cyclophosphamid...
18 Years - Mayo Clinic
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisNCT02593123
Hodgkin's Lymph...
Lymphoid Leukem...
Lymphoma
Leukemia
Myeloma
Acute Lymphocyt...
Non Hodgkin Lym...
Chronic Lymphoc...
Multiple Myelom...
Chronic Myeloge...
Myelodysplastic...
Recurrent Acute...
Recurrent Hodgk...
Recurrent Non-H...
Recurrent Plasm...
Recurrent Chron...
Recurrent Chron...
Acute Myelogeno...
mycophenolate m...
Sargramostim
Filgrastim
18 Years - 74 YearsVirginia Commonwealth University
Leflunomide in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT02509052
Recurrent Plasm...
Refractory Plas...
Laboratory Biom...
Leflunomide
Pharmacological...
18 Years - City of Hope Medical Center
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With LenalidomideNCT01794039
Recurrent Plasm...
Refractory Plas...
Dexamethasone
Lenalidomide
Pomalidomide
18 Years - Mayo Clinic
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaNCT01372540
Plasma Cell Leu...
Recurrent Plasm...
Refractory Plas...
Carfilzomib
Filanesib
Laboratory Biom...
18 Years - M.D. Anderson Cancer Center
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaNCT02119468
Refractory Plas...
Recurrent Plasm...
ixazomib citrat...
dexamethasone
pomalidomide
18 Years - City of Hope Medical Center
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT02353572
Plasma Cell Mye...
Plasmacytosis
Recurrent Plasm...
Smoldering Plas...
Melphalan
Bortezomib
Dexamethasone
Autologous Tran...
18 Years - 70 YearsUniversity of Colorado, Denver
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple MyelomaNCT02569320
Recurrent Plasm...
Dexamethasone
HDAC Inhibitor ...
Laboratory Biom...
Pomalidomide
18 Years - Ohio State University Comprehensive Cancer Center
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple MyelomaNCT03311828
Recurrent Plasm...
Plasma Cell Mye...
Secondary Amylo...
Daratumumab
Imaging Agent
Positron Emissi...
Pharmacological...
18 Years - City of Hope Medical Center
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaNCT04640779
Recurrent Histi...
Recurrent Hodgk...
Recurrent Non-H...
Recurrent Plasm...
Refractory Hist...
Refractory Hodg...
Refractory Non-...
Refractory Plas...
Choline Salicyl...
Selinexor
18 Years - Mayo Clinic
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaNCT03017820
B-Cell Non-Hodg...
Histiocytic and...
Myelodysplastic...
Previously Trea...
Recurrent Adult...
Recurrent Anapl...
Recurrent Angio...
Recurrent Mycos...
Recurrent Plasm...
Recurrent Prima...
Recurrent T-Cel...
Refractory Acut...
Refractory Anap...
Refractory Angi...
Refractory Myco...
Refractory Peri...
Refractory Plas...
Refractory Prim...
Refractory T-Ce...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Cyclophosphamid...
Positron Emissi...
Recombinant Ves...
Single Photon E...
Cemiplimab
18 Years - Mayo Clinic
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT01711528
Recurrent Plasm...
Bortezomib
Dexamethasone
Dinaciclib
Laboratory Biom...
18 Years - National Cancer Institute (NCI)
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaNCT01008462
B-Cell Prolymph...
Hypodiploidy
Loss of Chromos...
Plasma Cell Leu...
Progression of ...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Plasm...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Non-...
Refractory Plas...
Refractory Smal...
t(14;16)
t(4;14)
T-Cell Prolymph...
Waldenstrom Mac...
Allogeneic Bone...
Allogeneic Hema...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Peripheral Bloo...
Tacrolimus
Total-Body Irra...
- 75 YearsFred Hutchinson Cancer Center
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell TransplantNCT01231412
Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Lymphoc...
Diffuse Large B...
Hematopoietic a...
Indolent Non-Ho...
Mantle Cell Lym...
Myelodysplastic...
Myeloproliferat...
Prolymphocytic ...
Recurrent Chron...
Recurrent Plasm...
Refractory Chro...
Refractory Chro...
Refractory Hodg...
Small Lymphocyt...
T-Cell Chronic ...
Waldenstrom Mac...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Mycophenolate M...
Peripheral Bloo...
Sirolimus
Total-Body Irra...
- Fred Hutchinson Cancer Center
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple MyelomaNCT03267888
ISS Stage I Pla...
ISS Stage II Pl...
ISS Stage III P...
Recurrent Plasm...
Refractory Plas...
Pembrolizumab
Radiation Thera...
18 Years - Emory University
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT02353572
Plasma Cell Mye...
Plasmacytosis
Recurrent Plasm...
Smoldering Plas...
Melphalan
Bortezomib
Dexamethasone
Autologous Tran...
18 Years - 70 YearsUniversity of Colorado, Denver
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple MyelomaNCT04205240
Recurrent Plasm...
Allogeneic Hema...
Cyclophosphamid...
Daratumumab
Fludarabine
Melphalan
Mycophenolate M...
Tacrolimus
18 Years - 75 YearsOhio State University Comprehensive Cancer Center
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple MyelomaNCT03829020
Recurrent Plasm...
Refractory Plas...
Bortezomib
Metformin Hydro...
Nelfinavir Mesy...
18 Years - Mayo Clinic
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT03701321
Recurrent Plasm...
Refractory Plas...
Bortezomib
Daratumumab
Dexamethasone
Venetoclax
18 Years - National Cancer Institute (NCI)
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With DaratumumabNCT04407442
Recurrent Plasm...
Refractory Plas...
Azacitidine
Daratumumab
Dexamethasone
18 Years - University of California, San Francisco
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple MyelomaNCT03311828
Recurrent Plasm...
Plasma Cell Mye...
Secondary Amylo...
Daratumumab
Imaging Agent
Positron Emissi...
Pharmacological...
18 Years - City of Hope Medical Center
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple MyelomaNCT04756401
Recurrent Plasm...
Refractory Plas...
Carfilzomib
Daratumumab
Dexamethasone
Quality-of-Life...
Selinexor
18 Years - Academic and Community Cancer Research United
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT03841565
Recurrent Plasm...
Daratumumab
Dexamethasone
Pomalidomide
18 Years - Academic and Community Cancer Research United
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple MyelomaNCT04205240
Recurrent Plasm...
Allogeneic Hema...
Cyclophosphamid...
Daratumumab
Fludarabine
Melphalan
Mycophenolate M...
Tacrolimus
18 Years - 75 YearsOhio State University Comprehensive Cancer Center
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple MyelomaNCT02569320
Recurrent Plasm...
Dexamethasone
HDAC Inhibitor ...
Laboratory Biom...
Pomalidomide
18 Years - Ohio State University Comprehensive Cancer Center
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT02086552
Recurrent Plasm...
Refractory Plas...
Laboratory Biom...
Lenalidomide
Sonidegib
18 Years - Mayo Clinic
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT03333746
Recurrent Plasm...
Refractory Plas...
Laboratory Biom...
Lenalidomide
Nivolumab
Pharmacological...
18 Years - Ohio State University Comprehensive Cancer Center
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple MyelomaNCT03502577
Recurrent Plasm...
Refractory Plas...
BCMA-specific C...
Cyclophosphamid...
Fludarabine
Gamma-Secretase...
Laboratory Biom...
Pharmacokinetic...
21 Years - Fred Hutchinson Cancer Center
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaNCT01163357
Autologous Hema...
Loss of Chromos...
Plasma Cell Leu...
Recurrent Plasm...
Refractory Plas...
bortezomib
fludarabine pho...
melphalan
total marrow ir...
tacrolimus
sirolimus
peripheral bloo...
laboratory biom...
18 Years - 70 YearsCity of Hope Medical Center
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT01989598
Recurrent Plasm...
Refractory Plas...
Laboratory Biom...
Pharmacological...
Trametinib
Uprosertib
18 Years - National Cancer Institute (NCI)
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple MyelomaNCT04892264
Plasma Cell Mye...
Recurrent Plasm...
Refractory Plas...
Belantamab Mafo...
Daratumumab
Dexamethasone
Lenalidomide
Quality-of-Life...
Biospecimen Col...
Skeletal Survey...
Low Dose Comput...
Bone Marrow Asp...
Bone Marrow Bio...
18 Years - Mayo Clinic
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple MyelomaNCT03202628
Recurrent Plasm...
Refractory Plas...
Autologous Hema...
Dexamethasone
Ixazomib Citrat...
Laboratory Biom...
Pomalidomide
18 Years - Mayo Clinic
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT02633059
Loss of Chromos...
Recurrent Plasm...
Dexamethasone
Idasanutlin
Ixazomib Citrat...
Laboratory Biom...
Pharmacological...
18 Years - Mayo Clinic
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to BortezomibNCT01415882
Recurrent Plasm...
Refractory Plas...
Cyclophosphamid...
Daratumumab
Dexamethasone
Ixazomib Citrat...
Laboratory Biom...
18 Years - Mayo Clinic
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaNCT03017820
B-Cell Non-Hodg...
Histiocytic and...
Myelodysplastic...
Previously Trea...
Recurrent Adult...
Recurrent Anapl...
Recurrent Angio...
Recurrent Mycos...
Recurrent Plasm...
Recurrent Prima...
Recurrent T-Cel...
Refractory Acut...
Refractory Anap...
Refractory Angi...
Refractory Myco...
Refractory Peri...
Refractory Plas...
Refractory Prim...
Refractory T-Ce...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Cyclophosphamid...
Positron Emissi...
Recombinant Ves...
Single Photon E...
Cemiplimab
18 Years - Mayo Clinic
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaNCT02514382
Recurrent Plasm...
Refractory Plas...
Bortezomib
Dexamethasone
Laboratory Biom...
Pharmacological...
Wild-type Reovi...
18 Years - University of Southern California
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T TherapiesNCT05191472
Multiple Myelom...
Multiple Myelom...
Multiple Myelom...
Recurrent Plasm...
Refractory Plas...
Pembrolizumab
18 Years - University of California, San Francisco
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple MyelomaNCT03506802
HLA-A*0201 Posi...
NY-ESO-1 Positi...
Recurrent Plasm...
Refractory Plas...
18F-FHBG
Aldesleukin
Cellular Therap...
Computed Tomogr...
Filgrastim
Laboratory Biom...
Lenalidomide
Leukapheresis
Melphalan
Plerixafor
Positron Emissi...
18 Years - Jonsson Comprehensive Cancer Center
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple MyelomaNCT04205240
Recurrent Plasm...
Allogeneic Hema...
Cyclophosphamid...
Daratumumab
Fludarabine
Melphalan
Mycophenolate M...
Tacrolimus
18 Years - 75 YearsOhio State University Comprehensive Cancer Center
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaNCT04850599
Recurrent Plasm...
Refractory Plas...
Carfilzomib
Isatuximab
Pomalidomide
18 Years - OHSU Knight Cancer Institute
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantNCT03015792
Recurrent Plasm...
Refractory Plas...
Dexamethasone
Ibrutinib
Laboratory Biom...
Lenalidomide
Pharmacological...
Quality-of-Life...
18 Years - Mayo Clinic
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple MyelomaNCT04756401
Recurrent Plasm...
Refractory Plas...
Carfilzomib
Daratumumab
Dexamethasone
Quality-of-Life...
Selinexor
18 Years - Academic and Community Cancer Research United
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT02353572
Plasma Cell Mye...
Plasmacytosis
Recurrent Plasm...
Smoldering Plas...
Melphalan
Bortezomib
Dexamethasone
Autologous Tran...
18 Years - 70 YearsUniversity of Colorado, Denver
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaNCT01301807
Non-Secretory P...
Plasmacytosis
Recurrent Plasm...
Refractory Plas...
Carfilzomib
Panobinostat
18 Years - M.D. Anderson Cancer Center
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerNCT00789776
Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Diffuse Large B...
Previously Trea...
Recurrent Chron...
Recurrent Chron...
Recurrent Indol...
Recurrent Mantl...
Recurrent Plasm...
Recurrent Small...
Refractory Chro...
Refractory Hodg...
Refractory Plas...
Refractory Smal...
Waldenstrom Mac...
Allogeneic Bone...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Natural Killer ...
Tacrolimus
Total-Body Irra...
- Fred Hutchinson Cancer Center
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT01711528
Recurrent Plasm...
Bortezomib
Dexamethasone
Dinaciclib
Laboratory Biom...
18 Years - National Cancer Institute (NCI)
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With DaratumumabNCT04407442
Recurrent Plasm...
Refractory Plas...
Azacitidine
Daratumumab
Dexamethasone
18 Years - University of California, San Francisco
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT02633059
Loss of Chromos...
Recurrent Plasm...
Dexamethasone
Idasanutlin
Ixazomib Citrat...
Laboratory Biom...
Pharmacological...
18 Years - Mayo Clinic
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaNCT02506959
Plasma Cell Leu...
Plasmacytoma
Recurrent Plasm...
Refractory Plas...
Autologous Hema...
Busulfan
Gemcitabine Hyd...
Laboratory Biom...
Melphalan
Panobinostat
Peripheral Bloo...
Pharmacological...
18 Years - 65 YearsM.D. Anderson Cancer Center
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T TherapiesNCT05191472
Multiple Myelom...
Multiple Myelom...
Multiple Myelom...
Recurrent Plasm...
Refractory Plas...
Pembrolizumab
18 Years - University of California, San Francisco
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell TransplantNCT03622775
Recurrent Plasm...
Daratumumab
18 Years - M.D. Anderson Cancer Center
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaNCT01163357
Autologous Hema...
Loss of Chromos...
Plasma Cell Leu...
Recurrent Plasm...
Refractory Plas...
bortezomib
fludarabine pho...
melphalan
total marrow ir...
tacrolimus
sirolimus
peripheral bloo...
laboratory biom...
18 Years - 70 YearsCity of Hope Medical Center
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaNCT01372540
Plasma Cell Leu...
Recurrent Plasm...
Refractory Plas...
Carfilzomib
Filanesib
Laboratory Biom...
18 Years - M.D. Anderson Cancer Center
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic LeukemiaNCT02948283
Anemia
Fatigue
Fever
Lymphadenopathy
Lymphocytosis
Night Sweats
Recurrent Chron...
Recurrent Plasm...
Refractory Chro...
Refractory Plas...
Splenomegaly
Thrombocytopeni...
Weight Loss
Laboratory Biom...
Metformin Hydro...
Pharmacological...
Ritonavir
Quality-of-Life
Questionnaire
18 Years - City of Hope Medical Center
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple MyelomaNCT00450814
Recurrent Plasm...
Refractory Plas...
Cyclophosphamid...
Laboratory Biom...
Oncolytic Measl...
Pharmacological...
18 Years - Mayo Clinic
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple MyelomaNCT00450814
Recurrent Plasm...
Refractory Plas...
Cyclophosphamid...
Laboratory Biom...
Oncolytic Measl...
Pharmacological...
18 Years - Mayo Clinic
Study of Personalized Melphalan Dosing in the Setting of Autologous TransplantNCT03328936
Hematopoietic C...
Recurrent Plasm...
Refractory Plas...
Laboratory Biom...
Melphalan Hydro...
Melphalan Hydro...
Pharmacological...
18 Years - Ohio State University Comprehensive Cancer Center
Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaNCT02697344
Recurrent Plasm...
Dexamethasone
Laboratory Biom...
Lenalidomide
Pharmacological...
R-(-)-Gossypol ...
18 Years - Mayo Clinic
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaNCT02506959
Plasma Cell Leu...
Plasmacytoma
Recurrent Plasm...
Refractory Plas...
Autologous Hema...
Busulfan
Gemcitabine Hyd...
Laboratory Biom...
Melphalan
Panobinostat
Peripheral Bloo...
Pharmacological...
18 Years - 65 YearsM.D. Anderson Cancer Center
Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple MyelomaNCT03829020
Recurrent Plasm...
Refractory Plas...
Bortezomib
Metformin Hydro...
Nelfinavir Mesy...
18 Years - Mayo Clinic
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaNCT03399539
Recurrent Plasm...
t(11;14)
Dexamethasone
Ixazomib Citrat...
Laboratory Biom...
Venetoclax
18 Years - Mayo Clinic
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: